Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

Ma, LL; Zhu, M; Li, GH; Gai, JW; Li, YF; Gu, HY; Qiao, P; Li, XF; Ji, WW; Zhao, R; Wu, Y; Wan, YK

Wan, YK (通讯作者),Shanghai Novamab Biopharmaceut Co Ltd, Shanghai, Peoples R China.

RESPIRATORY RESEARCH, 2022; 23 (1):

Abstract

Background: Eosinophilic asthma is a common subtype of severe asthma with high morbidity and mortality. The cytokine IL-5 has been shown to be a key d......

Full Text Link